Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Serum Biomarker Detects Colorectal Cancer Early

By LabMedica International staff writers
Posted on 26 Jun 2013
A noninvasive molecular test has been developed that measures methylation of a gene in tissues and blood sera as a biomarker for the early detection of cancer.

The gene was identified as the syndecan-2 (SDC2) gene, which encodes for the membrane syndecan-2 protein that is known to participate in cell proliferation, cell migration, and is expressed in colon mesenchymal cells.

Scientists at the Yonsei University College of Medicine (Seoul, Republic of Korea) working with colleagues at Genomictree, Inc. (Daejeon, Republic of Korea) performed DNA microarray analysis coupled with enriched methylated DNA using tissues from primary tumors and nontumor tissues from 12 Colorectal Cancer (CRC) patients. After stepwise filtering, they found a set of genes that were highly methylated across all of the CRC tumors, and of particular importance was SDC2. The methylation level of target region of SDC2 assessed in tumor tissue was found to be significantly higher than that from paired adjacent nontumor tissue.

The biomarker was validated by analyzing SDC2 methylation levels in primary tumors and paired-adjacent nontumor tissue samples from 133 CRC patients. The investigators found that in the transcriptional regulatory region of the SDC2 gene, tumor samples showed significantly higher levels of methylation than the control samples. The SDC2 methylation positivity ranged from 92.9% to 100% when samples were stratified according to stages of cancer. The SDC2 biomarker could also be measured in serum samples from CRC patients and healthy individuals.

Fluorescence-based quantitative methylation-specific polymerase chain reaction (qMSP) was used to determine SDC2 methylation in the serum DNA.

TaeJeong Oh, PhD, the lead author of the study said, “The SDC2 methylation test was able to detect 92% for detection of stage I cancer patients indicating that SDC2 is suitable for early detection of CRC where therapeutic interventions have the greatest likelihood of curing the patient from the disease.” Sungwhan An, PhD, CEO of Genomictree and senior author of the study, said, “We are very excited with this result using a small amount of serum DNA from less than 1 mL of blood. I believe a greater volume of blood will further improve the clinical performance of this test. We are currently preparing another set of clinical validation studies evaluating SDC2 methylation in serum DNA from patients with early adenoma.” The study was published on June 7, 2013, in the Journal of Molecular Diagnostics.

Related Links:

Yonsei University College of Medicine
Genomictree, Inc.



Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Myeloperoxidase Assay
IDK MPO ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.